John Dahldorf has just joined Benvenue Medical, Inc. as the company’s chief financial officer (CFO). Dahldorf, who has more than 30 years of financial, operational and leadership experience in the healthcare industry, was most recently CFO at Volcano Corporation.
John Dahldorf Takes Helm as CFO at Benvenue Medical

“I was looking for a great management team and a portfolio of medical technology that has strong growth potential, and I found it in Benvenue Medical, ” Dahldorf said in the March 23, 2015 news release. “Benvenue’s products, Luna and Kiva, have entered a $3.2 billion U.S. market that’s historically had very little innovation. I believe Benvenue has potential similar to what I experienced at Volcano, where we grew from virtually zero to $400 million in 11 years.”
“John brings invaluable experience with private and public companies, including being chief financial officer at a publicly traded company, ” said Robert Weigle, CEO of Benvenue Medical, Inc. “His strong reputation, experience in the investment community and expertise in public markets will be advantageous for achieving our future business plans.”
Dahldorf told OTW, “As I move forward in this new role at Benvenue, my first steps will be to work closely with the senior management team to build both short- and long-term business strategies and to ensure our capital needs are met. I’ll be participating in meetings internally and externally to assess where Benvenue is and where we want to go, and explore our options to get there.”
Dahldorf’s previous experience includes co-chief executive officer and chief financial officer at Digirad Corporation, finance director at Arrow Electronics, and a number of leadership positions at Baxter companies. He earned his master of business administration and bachelor of finance degrees at Western Illinois University.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.